294 related articles for article (PubMed ID: 27442248)
1. 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored.
Pretorius E; Africander DJ; Vlok M; Perkins MS; Quanson J; Storbeck KH
PLoS One; 2016; 11(7):e0159867. PubMed ID: 27442248
[TBL] [Abstract][Full Text] [Related]
2. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
3. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
[TBL] [Abstract][Full Text] [Related]
4. Profiles of 5α-Reduced Androgens in Humans and Eels: 5α-Dihydrotestosterone and 11-Ketodihydrotestosterone Are Active Androgens Produced in Eel Gonads.
Yazawa T; Inaba H; Imamichi Y; Sekiguchi T; Uwada J; Islam MS; Orisaka M; Mikami D; Ida T; Sato T; Miyashiro Y; Takahashi S; Khan MRI; Suzuki N; Umezawa A; Kitano T
Front Endocrinol (Lausanne); 2021; 12():657360. PubMed ID: 33833737
[TBL] [Abstract][Full Text] [Related]
5. Inefficient UGT-conjugation of adrenal 11β-hydroxyandrostenedione metabolites highlights C11-oxy C
du Toit T; Swart AC
Mol Cell Endocrinol; 2018 Feb; 461():265-276. PubMed ID: 28939401
[TBL] [Abstract][Full Text] [Related]
6. A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids.
Pretorius E; Arlt W; Storbeck KH
Mol Cell Endocrinol; 2017 Feb; 441():76-85. PubMed ID: 27519632
[TBL] [Abstract][Full Text] [Related]
7. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.
Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P
J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396
[TBL] [Abstract][Full Text] [Related]
8. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
9. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
Ming DS; Pham S; Deb S; Chin MY; Kharmate G; Adomat H; Beheshti EH; Locke J; Guns ET
J Steroid Biochem Mol Biol; 2014 Sep; 143():19-28. PubMed ID: 24565566
[TBL] [Abstract][Full Text] [Related]
10. Steroidogenesis in castration-resistant prostate cancer.
Shiota M; Endo S; Blas L; Fujimoto N; Eto M
Urol Oncol; 2023 May; 41(5):240-251. PubMed ID: 36376200
[TBL] [Abstract][Full Text] [Related]
11. The 11β-hydroxyandrostenedione pathway and C11-oxy C
du Toit T; Swart AC
J Steroid Biochem Mol Biol; 2020 Feb; 196():105497. PubMed ID: 31626910
[TBL] [Abstract][Full Text] [Related]
12. 11β-Hydroxyandrostenedione: Downstream metabolism by 11βHSD, 17βHSD and SRD5A produces novel substrates in familiar pathways.
Swart AC; Storbeck KH
Mol Cell Endocrinol; 2015 Jun; 408():114-23. PubMed ID: 25542845
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
14. C11-hydroxy and C11-oxo C
Gent R; Van Rooyen D; Atkin SL; Swart AC
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203272
[TBL] [Abstract][Full Text] [Related]
15. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
Mostaghel EA
Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
[TBL] [Abstract][Full Text] [Related]
16. 11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration.
Snaterse G; van Dessel LF; van Riet J; Taylor AE; van der Vlugt-Daane M; Hamberg P; de Wit R; Visser JA; Arlt W; Lolkema MP; Hofland J
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33974560
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.
Knuuttila M; Mehmood A; Huhtaniemi R; Yatkin E; Häkkinen MR; Oksala R; Laajala TD; Ryberg H; Handelsman DJ; Aittokallio T; Auriola S; Ohlsson C; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Am J Pathol; 2018 Jan; 188(1):216-228. PubMed ID: 29126837
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
